Ciclosporin and ketoconazole in cats: the label warning and its limits
Published: · Updated:
The Atopica label identifies a clinically relevant increase in ciclosporin blood concentrations with ketoconazole in cats, but its numerical example and interval advice concern dogs.
Short answer
Ketoconazole can increase ciclosporin blood concentrations in cats, an interaction the Atopica oral-solution label considers clinically relevant. The label does not quantify the increase in cats or provide a feline ketoconazole-specific adjustment; its numerical example and advice to consider doubling the treatment interval explicitly concern dogs. [1]
Compare the evidence
| Source and design | Population or scope | Finding | Limits |
|---|---|---|---|
| Official product label: interaction statement, section 4.8 [1] | Atopica 100 mg/ml oral ciclosporin solution; the general azole warning includes cats and dogs | Azoles such as ketoconazole are known to increase ciclosporin blood concentrations in cats and dogs, which the label considers clinically relevant. | The passage provides no feline effect size, sample size, clinical-event frequency or ketoconazole-specific feline adjustment. Its numerical example and treatment-interval advice are explicitly canine. |
| Same official product label: feline pharmacokinetics, section 5.2 [1] | Cats at the recommended ciclosporin dosage; not a reported ketoconazole combination experiment | Feline plasma concentrations show large inter-individual variation and do not predict clinical response at the recommended dosage; the label therefore does not recommend blood-level monitoring. | This is context from the same source, not independent confirmation of the interaction or a combination-specific monitoring protocol. |
Which feline product and treatment does this evidence concern?
The source is the Summary of Product Characteristics for Atopica 100 mg/ml Oral Solution for Cats and Dogs. Its feline indication is symptomatic treatment of chronic allergic dermatitis. This is product-label evidence, not a comparison of different ciclosporin formulations in cats. [1]
Does the dog's fivefold concentration example apply to cats?
No. Although the general ketoconazole warning explicitly includes cats, the subsequent example of an increase up to fivefold identifies dogs. The accompanying advice for a veterinarian to consider doubling the treatment interval also specifies a dog on daily treatment. Neither statement establishes a feline exposure multiplier or adjustment plan. [1]
Does the cat label recommend routine ciclosporin blood-level monitoring?
In its feline pharmacokinetic section, the label states that plasma concentrations vary greatly between individuals and, at the recommended dosage, do not predict clinical response; it therefore does not recommend blood-level monitoring. That statement is not a ketoconazole co-administration study and supplies no testing schedule for this combination. [1]
How does the label assess the cat's dermatitis response?
The feline administration section assesses improvement through itch intensity and skin-lesion severity, with subsequent administration frequency depending on response and regular re-evaluation. These are general Atopica treatment instructions, not a tested correction for the ketoconazole interaction. [1]
Evidence appraisal: feline warning versus canine measurements
Section 4.8 discusses enzymes involved in ciclosporin metabolism, particularly CYP3A4, before identifying the clinically relevant azole-associated concentration increase in cats and dogs. It does not report a feline ketoconazole experiment with a sample size, measured exposure ratio or clinical outcomes. The warning supports the direction of the concentration change, but does not quantify the likelihood of harm in a cat. The dog-specific example cannot fill those feline evidence gaps. [1]
Clinical interpretation: response-guided care is not an interaction formula
Keep the label's two discussions separate: section 4.8 identifies increased ciclosporin concentrations with ketoconazole, while the feline administration section adjusts treatment frequency according to dermatitis response. The latter does not establish how to compensate for ketoconazole. Neither section supplies a feline ketoconazole-specific dose correction, spacing interval or washout period. [1]
Questions for veterinary review
Editorial discussion checklist for your veterinarian:
- Editorial discussion aid, not a treatment protocol: bring the exact ciclosporin and ketoconazole products and actual administration history to the prescribing veterinarian.
- Ask how the cat's dermatitis response informs assessment of the combination, rather than transferring the dog concentration example or interval advice.
- Do not derive a feline dose correction, testing schedule or washout period from this page.
Catalogue review status and evidence limits
The catalogue records contain verified direct evidence (cat): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.
A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.
Evidence sources
Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.
- VMD: Atopica 100 mg/ml Oral Solution for Cats and Dogs — Summary of Product Characteristics
Evidence type: Official product label. Revised September 2025. 4.8, interactions. Page 5. Source checked: . Open official VMD source
Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.